Any American who has paid the price of a patent-protected medicine knows the core flaw in the U.S. prescription drug system: our elected leaders have handed over control to profit-hungry corporations. And for-profit corporations gonna for-profit, as the kids would say. That is especially true when the corporations are gifted with long-term monopolies on life-essential medicines, which gives them the leverage to set take-it-or-leave it prices that net billions in revenue extracted from all of us. It doesn’t have to be this way. That is the message of an exciting new report, "Medicine for All: The Case for a Public Option in the Pharmaceutical Industry," by Dana Brown, director of the Next System Project of the organization Democracy Collaborative.